TRAIL-R3 is a decoy protein which can be bypassed by targeting TRAIL-R1 and TRAIL-R2 by antibodies and thus can be used as a treatment for AML patients (112). The gene discussed is TNFRSF10C; the disease is acute myeloid leukemia.